SK14162002A3 - Kombinácia obsahujúca paracetamol alebo nesteroidné protizápalové liečivo, použitie mirtazapínu, paracetamolu a pacientský balíček - Google Patents

Kombinácia obsahujúca paracetamol alebo nesteroidné protizápalové liečivo, použitie mirtazapínu, paracetamolu a pacientský balíček Download PDF

Info

Publication number: SK14162002A3
Authority: SK; Slovakia
Prior art keywords: mirtazapine; headache; treatment; combination; paracetamol
Prior art date: 2000-04-05

Application number

SK1416-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Victor Johannes Nickolson

Original Assignee

Akzo Nobel N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-05

Filing date

2001-04-04

Publication date

2003-03-04

2001-04-04 Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.

2003-03-04 Publication of SK14162002A3 publication Critical patent/SK14162002A3/sk

Links

RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims abstract description 72
229960001785 mirtazapine Drugs 0.000 title claims abstract description 70
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims abstract description 59
206010019233 Headaches Diseases 0.000 title claims abstract description 46
231100000869 headache Toxicity 0.000 title claims abstract description 45
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 44
229960005489 paracetamol Drugs 0.000 title claims abstract description 44
238000011282 treatment Methods 0.000 title claims abstract description 40
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title claims abstract description 39
239000000890 drug combination Substances 0.000 title 1
239000003814 drug Substances 0.000 claims abstract description 36
229940079593 drug Drugs 0.000 claims abstract description 24
150000003839 salts Chemical class 0.000 claims abstract description 22
238000000034 method Methods 0.000 claims abstract description 17
239000012453 solvate Substances 0.000 claims abstract description 15
239000003937 drug carrier Substances 0.000 claims abstract description 8
208000008548 Tension-Type Headache Diseases 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 11
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 9
229960001680 ibuprofen Drugs 0.000 claims description 9
206010043269 Tension headache Diseases 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
239000000203 mixture Substances 0.000 abstract description 25
230000000694 effects Effects 0.000 abstract description 15
230000002349 favourable effect Effects 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 description 15
239000003826 tablet Substances 0.000 description 13
238000009472 formulation Methods 0.000 description 9
150000001875 compounds Chemical class 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
239000008101 lactose Substances 0.000 description 7
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
-1 FR 140423 Chemical compound 0.000 description 4
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000002775 capsule Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
239000000730 antalgic agent Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
229910002012 Aerosil® Inorganic materials 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Chemical class 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
229960003184 carprofen Drugs 0.000 description 2
IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
229960005293 etodolac Drugs 0.000 description 2
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
229950005722 flosulide Drugs 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 description 2
229960004270 nabumetone Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 2
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
239000008107 starch Chemical class 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DTOPKPBTCXKNFF-SNVBAGLBSA-N (2r)-2-[4-(3-methylthiophen-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1C1=C(C)C=CS1 DTOPKPBTCXKNFF-SNVBAGLBSA-N 0.000 description 1
GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960004420 aceclofenac Drugs 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000001705 anti-serotonergic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960005430 benoxaprofen Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002973 butibufen Drugs 0.000 description 1
UULSXYSSHHRCQK-UHFFFAOYSA-N butibufen Chemical compound CCC(C(O)=O)C1=CC=C(CC(C)C)C=C1 UULSXYSSHHRCQK-UHFFFAOYSA-N 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
CVNFYQCHAWFYQI-ZSCHJXSPSA-N clonixin lysine salt Chemical compound NCCCC[C@H](N)C(O)=O.CC1=C(Cl)C=CC=C1NC1=NC=CC=C1C(O)=O CVNFYQCHAWFYQI-ZSCHJXSPSA-N 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940120889 dipyrone Drugs 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229960003133 ergot alkaloid Drugs 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
229960002390 flurbiprofen Drugs 0.000 description 1
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
239000003906 humectant Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
229950009183 ibufenac Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003763 lysine clonixinate Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
229960003803 meclofenamic acid Drugs 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
230000031990 negative regulation of inflammatory response Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
229960005222 phenazone Drugs 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
229940023942 remeron Drugs 0.000 description 1
150000003902 salicylic acid esters Chemical class 0.000 description 1
229960000953 salsalate Drugs 0.000 description 1
208000018316 severe headache Diseases 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
229960003676 tenidap Drugs 0.000 description 1
LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
229960002871 tenoxicam Drugs 0.000 description 1
WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
229950009638 tepoxalin Drugs 0.000 description 1
XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960001312 tiaprofenic acid Drugs 0.000 description 1
229960002905 tolfenamic acid Drugs 0.000 description 1
YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
229950004227 zaltoprofen Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1416-2002A 2000-04-05 2001-04-04 Kombinácia obsahujúca paracetamol alebo nesteroidné protizápalové liečivo, použitie mirtazapínu, paracetamolu a pacientský balíček SK14162002A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00201239		2000-04-05
PCT/EP2001/004069 WO2001074340A2 (en)	2000-04-05	2001-04-04	Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug

Publications (1)

Publication Number	Publication Date
SK14162002A3 true SK14162002A3 (sk)	2003-03-04

Family

ID=8171309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1416-2002A SK14162002A3 (sk)	2000-04-05	2001-04-04	Kombinácia obsahujúca paracetamol alebo nesteroidné protizápalové liečivo, použitie mirtazapínu, paracetamolu a pacientský balíček

Country Status (24)

Country	Link
EP (1)	EP1242092B1 (de)
JP (1)	JP2004500410A (de)
KR (1)	KR20020086945A (de)
CN (1)	CN1537006A (de)
AT (1)	ATE244010T1 (de)
AU (2)	AU2001273932B2 (de)
BR (1)	BR0109881A (de)
CA (1)	CA2404358A1 (de)
CZ (1)	CZ295982B6 (de)
DE (1)	DE60100431T2 (de)
DK (1)	DK1242092T3 (de)
ES (1)	ES2201039T3 (de)
HK (1)	HK1047547B (de)
HU (1)	HUP0300717A3 (de)
IL (1)	IL151815A0 (de)
MX (1)	MXPA02009811A (de)
NO (1)	NO20024684L (de)
NZ (1)	NZ521631A (de)
PL (1)	PL366237A1 (de)
PT (1)	PT1242092E (de)
RU (1)	RU2002129356A (de)
SK (1)	SK14162002A3 (de)
WO (1)	WO2001074340A2 (de)
ZA (1)	ZA200207701B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200538100A (en) *	2004-04-21	2005-12-01	Akzo Nobel Nv	Mirtazapine salts
DE102004034043A1 (de) *	2004-07-13	2006-02-09	Krka Tovarna Zdravil, D.D.	Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
EP1792618A1 (de) *	2005-11-30	2007-06-06	Rainer Freynhagen	R-mirtazapine zur Behandlung von Schmerz
WO2020229388A1 (en)	2019-05-12	2020-11-19	Curatis Ag	Mirtazapine for use in medication overuse headache based on tension-type headache
KR102549596B1 (ko)	2021-12-14	2023-07-03	재단법인 환동해산업연구원	생리활성을 가지는 사카이대마디말 추출물 및 그 제조방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998019674A2 (en) *	1996-11-05	1998-05-14	Head Explorer Aps	A method for treating tension-type headache

2001
- 2001-04-04 DE DE60100431T patent/DE60100431T2/de not_active Expired - Fee Related
- 2001-04-04 ES ES01940311T patent/ES2201039T3/es not_active Expired - Lifetime
- 2001-04-04 HK HK02109167.6A patent/HK1047547B/en not_active IP Right Cessation
- 2001-04-04 PT PT01940311T patent/PT1242092E/pt unknown
- 2001-04-04 WO PCT/EP2001/004069 patent/WO2001074340A2/en not_active Ceased
- 2001-04-04 RU RU2002129356/15A patent/RU2002129356A/ru not_active Application Discontinuation
- 2001-04-04 KR KR1020027013286A patent/KR20020086945A/ko not_active Withdrawn
- 2001-04-04 AU AU2001273932A patent/AU2001273932B2/en not_active Ceased
- 2001-04-04 CN CNA018075444A patent/CN1537006A/zh active Pending
- 2001-04-04 AT AT01940311T patent/ATE244010T1/de not_active IP Right Cessation
- 2001-04-04 EP EP01940311A patent/EP1242092B1/de not_active Expired - Lifetime
- 2001-04-04 NZ NZ521631A patent/NZ521631A/en unknown
- 2001-04-04 DK DK01940311T patent/DK1242092T3/da active
- 2001-04-04 PL PL01366237A patent/PL366237A1/xx not_active Application Discontinuation
- 2001-04-04 CZ CZ20023322A patent/CZ295982B6/cs not_active IP Right Cessation
- 2001-04-04 CA CA002404358A patent/CA2404358A1/en not_active Abandoned
- 2001-04-04 HU HU0300717A patent/HUP0300717A3/hu unknown
- 2001-04-04 BR BR0109881-0A patent/BR0109881A/pt not_active IP Right Cessation
- 2001-04-04 IL IL15181501A patent/IL151815A0/xx unknown
- 2001-04-04 SK SK1416-2002A patent/SK14162002A3/sk unknown
- 2001-04-04 MX MXPA02009811A patent/MXPA02009811A/es active IP Right Grant
- 2001-04-04 AU AU7393201A patent/AU7393201A/xx active Pending
- 2001-04-04 JP JP2001572085A patent/JP2004500410A/ja not_active Withdrawn
2002
- 2002-09-25 ZA ZA200207701A patent/ZA200207701B/en unknown
- 2002-09-30 NO NO20024684A patent/NO20024684L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE60100431D1 (de)	2003-08-07
DK1242092T3 (da)	2003-10-06
WO2001074340A3 (en)	2002-07-18
ZA200207701B (en)	2004-02-10
KR20020086945A (ko)	2002-11-20
HK1047547A1 (en)	2003-02-28
EP1242092B1 (de)	2003-07-02
HK1047547B (en)	2003-10-10
CA2404358A1 (en)	2001-10-11
MXPA02009811A (es)	2003-05-27
ATE244010T1 (de)	2003-07-15
JP2004500410A (ja)	2004-01-08
WO2001074340A2 (en)	2001-10-11
RU2002129356A (ru)	2004-03-27
AU2001273932B2 (en)	2005-07-14
NO20024684L (no)	2002-11-21
IL151815A0 (en)	2003-04-10
HUP0300717A3 (en)	2004-11-29
NO20024684D0 (no)	2002-09-30
ES2201039T3 (es)	2004-03-16
PL366237A1 (en)	2005-01-24
CZ295982B6 (cs)	2005-12-14
AU7393201A (en)	2001-10-15
CN1537006A (zh)	2004-10-13
NZ521631A (en)	2005-01-28
DE60100431T2 (de)	2004-05-19
CZ20023322A3 (cs)	2003-01-15
PT1242092E (pt)	2003-11-28
BR0109881A (pt)	2003-06-03
EP1242092A2 (de)	2002-09-25
HUP0300717A2 (hu)	2003-07-28

Publication	Publication Date	Title
JP4925074B2 (ja)	2012-04-25	ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
CA2260943C (en)	2006-11-07	Formulation of 5-ht agonists
US6511985B1 (en)	2003-01-28	Combination of cerivastatin and fibrates
US7834056B2 (en)	2010-11-16	Pharmaceutical composition for gout
KR20050047560A (ko)	2005-05-20	안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는약제학적 조합물
CZ20023381A3 (cs)	2003-02-12	Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor
AU5030399A (en)	2000-02-01	Agents with an antidepressive effect
CN101588797A (zh)	2009-11-25	带有最小化副作用包括减轻肝毒性的对乙酰氨基酚组合物
KR102597910B1 (ko)	2023-11-02	숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
CN101702884A (zh)	2010-05-05	用于治疗高血糖症及相关病症的脂肪酸氧化抑制剂
EP1673107B1 (de)	2008-03-26	Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker
AU2009201201A1 (en)	2009-04-30	Novel pharmaceutical composition
EP1242092B1 (de)	2003-07-02	Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln
KR100692235B1 (ko)	2007-03-09	안지오텐신 ⅱ 길항물질의 신규한 용도
AU2001273932A1 (en)	2002-01-03	Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
US20100249103A1 (en)	2010-09-30	combination treatment
JP2024534156A (ja)	2024-09-18	Ｎｕｒｒ１アゴニストの、アルドステロンアンタゴニスト、インスリンモジュレーター及びスルホニル尿素のうちの少なくとも１つとの組合せ
AU2005205914A1 (en)	2005-08-04	Combination of organic compounds
Hussar	2021	New Drugs 2021, Part 2
JP2023544224A (ja)	2023-10-20	ヒト低コリン作動性障害の処置のための医薬の組合せ
US20130150375A1 (en)	2013-06-13	GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
US20050192355A1 (en)	2005-09-01	Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
HK1132196A (en)	2010-02-19	Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
HK1117735A (en)	2009-01-23	Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes